| 1277 |
Diabetics in the ENDEAVOR IV Trial: Three Year Clinical Outcomes |
|
Oct. 18. 10 |
| 1276 |
A Randomized Trial to Confirm the Safety and Efficacy of the Medtronic Zotarolimus Eluting Coronary Stent in De Novo Native Coronary Artery Lesions |
|
Oct. 18. 10 |
| 1275 |
A Phase 2, Randomized, Parallel Group, Dose Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE-Xa) |
|
Oct. 18. 10 |
| 1274 |
Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE) |
|
Oct. 18. 10 |
| 1273 |
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction: 3 year follow-up of the randomised DEDICATION trial |
|
Oct. 18. 10 |
| 1272 |
Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation |
|
Oct. 18. 10 |
| 1271 |
The Anglo-Scandinavian Cardiac Outcomes Trial –Blood Pressure Lowering Arm (ASCOT-BPLA) |
|
Oct. 18. 10 |
| 1270 |
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial |
|
Oct. 18. 10 |
| 1269 |
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial |
|
Oct. 18. 10 |
| 1268 |
Behind Closed Doors: Functions of a Data Safety Monitoring Board |
Roxana Mehran |
May. 04. 10 |
